Ciglitazone
Ciglitazone is a potent and selective PPARγ agonist (EC50=3 μM) . Ciglitazone inhibits proliferation and differentiation of th17 cells. Ciglitazone is a hypoglycemic agent orally active in the obese-hyperglycemic animal models. Ciglitazone induces apoptosis accompanied by activation of p38 MAPK and nuclear translocation of apoptosis inducing factor (AIF) in opossum kidney (OK) renal epithelial cells[1][2][3][4].
Product Specifications
CAS Number
74772-77-3
Product Name Alternative
ADD-3878; U-63287
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
PPAR
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Applications
Cancer-programmed cell death
Field of Research
Cancer; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/ciglitazone.html
Purity
99.74
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C(N1)SC(CC2=CC=C(OCC3(C)CCCCC3)C=C2)C1=O
Molecular Formula
C18H23NO3S
Molecular Weight
333.45
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
STING1 Human Recombinant Protein, Synthetic Nanodisc
